TherapeuticsMD (TXMD) Misses Q4 EPS by 5c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $22.6 million versus the consensus estimate of $21.89 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets
• Oppenheimer Starts Teva Pharma (TEVA) at Outperform